At A Glance:

Opioid-induced constipation (OIC) is projected to hit $2.8 billion by 2022, according to Credence Research (March 2016 report). Growth for this market will come from the introduction of several new drugs, including this sponsor’s compound, which would be the first to market in a new class.

Download PDF
Indication:

Opioid-Induced Constipation

Site enrollment rate increase: 77%
Cost savings: $13.9 million
(vs. adding sites)
See the results
Case Study

AES Shortens Timelines by up to 20 Months for a Uterine Fibroid Program

VIEW CASE STUDY >
Case Study

AES Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

VIEW CASE STUDY >
Case Study

AES saves up to 76 months of enrollment time for this pediatric depression program

VIEW CASE STUDY >
Case Study

AES Shortens Enrollment by 7 Months for a Crucial Migraine Phase IIb Study

VIEW CASE STUDY >
Case Study

AES Saves More than 4 Months of Enrollment Time and $2.2 Million for Phase III Atopic Dermatitis Study

VIEW CASE STUDY >